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Summary
Background Use of biological or synthetic mesh might improve outcomes of immediate implant-based breast 
reconstruction—breast reconstruction with implants or expanders at the time of mastectomy—but there is a lack of 
high-quality evidence to support the safety or effectiveness of the technique. We aimed to establish the short-term 
safety of immediate implant-based breast reconstruction performed with and without mesh, to inform the feasibility 
of undertaking a future randomised clinical trial comparing different breast reconstruction techniques.
Methods In this prospective, multicentre cohort study, we consecutively recruited women aged 16 years or older who 
had any type of immediate implant-based breast reconstruction for malignancy or risk reduction, with any technique, 
at 81 participating breast and plastic surgical units in the UK. Data about patient demographics and operative, 
oncological, and complication details were collected before and after surgery. Outcomes of interest were implant loss 
(defined as unplanned removal of the expander or implant), infection requiring treatment with antibiotics or surgery, 
unplanned return to theatre, and unplanned re-admission to hospital for complications of reconstructive surgery, 
up to 3 months after reconstruction and assessed by clinical review or patient self-report. Follow-up is complete. The 
study is registered with the ISRCTN Registry, number ISRCTN37664281.
Findings Between Feb 1, 2014, and June 30, 2016, 2108 patients had 2655 mastectomies with immediate implant-based 
breast reconstruction at 81 units across the UK. 1650 (78%) patients had planned single-stage reconstructions 
(including 12 patients who had a different technique per breast). 1376 (65%) patients had reconstruction with 
biological (1133 [54%]) or synthetic (243 [12%]) mesh, 181 (9%) had non-mesh submuscular or subfascial implants, 
440 (21%) had dermal sling implants, 42 (2%) had pre-pectoral implants, and 79 (4%) had other or a combination of 
implants. 3-month outcome data were available for 2081 (99%) patients. Of these patients, 182 (9%, 95% CI 8–10) 
experienced implant loss, 372 (18%, 16–20) required re-admission to hospital, and 370 (18%, 16–20) required return 
to theatre for complications within 3 months of their initial surgery. 522 (25%, 95% CI 23–27) patients required 
treatment for an infection. The rates of all of these complications are higher than those in the National Quality 
Standards (<5% for re-operation, re-admission, and implant loss, and <10% for infection).
Interpretation Complications after immediate implant-based breast reconstruction are higher than recommended by 
national standards. A randomised clinical trial is needed to establish the optimal approach to immediate implant-
based breast reconstruction.
Funding National Institute for Health Research, Association of Breast Surgery, and British Association of Plastic, 
Reconstructive and Aesthetic Surgeons.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Up to 40% of the 1·7 million women diagnosed with 
breast cancer each year will require a mastectomy as the 
surgical treatment for their disease.1–3 Mastectomy can 
profoundly affect body image and self-esteem, and 
immediate breast reconstruction, performed at the time 
of mastectomy, is offered to improve quality of life.4
Implant-based breast reconstruction is the most 
commonly performed reconstructive procedure world-
wide.5,6 Traditionally, a two-stage procedure is done, 
involving the initial placement of a tissue expander in the 
subpectoral pocket, sequential expansions with saline 
until the desired volume is achieved, and replacement of 
the expander with a fixed-volume implant. The 
introduction of biological and synthetic meshes have 
revolutionised this technique. The mesh is sutured 
between the lower edge of the pectoralis muscle and the 
chest wall to create a larger subpectoral pocket that can 
accommodate a fixed-volume implant at the time of the 
initial surgery. This approach facilitates single-stage 
direct-to-implant reconstruction without the need for a 
second procedure, with substantial associated benefits for 
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patients and health-care providers. The mesh can improve 
cosmetic outcomes by allowing improved lower-pole 
projection and creating a more natural-looking ptotic 
result. A range of biological (eg, acellular dermal matrix 
[ADM]) and synthetic (eg, titanium-coated polypropylene) 
meshes are available. These meshes differ notably in price 
and, in the absence of comparative evidence, product 
selection is largely dependent on surgeon preference.
The practice of immediate implant-based breast 
reconstruction has evolved further with the introduction 
of so-called muscle-sparing techniques.7 These 
techniques involve wrapping the implant in mesh and 
placing it on top of, rather than underneath, the pectoralis 
muscle. This pre-pectoral technique might further 
improve outcomes for patients by reducing postoperative 
pain and preventing implant animation, the upward 
movement of the implant seen when the pectoralis 
muscle contracts.7
Despite the widespread adoption of mesh-assisted 
techniques into practice, evidence to support the 
proposed benefits of mesh is lacking.7–10 A multicentre 
Dutch randomised controlled trial11 showed significantly 
increased numbers of complications in single-stage, 
direct-to-implant reconstruction with mesh compared 
with standard two-stage expander-implant techniques. 
The study was criticised because the participating 
surgeons had limited experience with the technique,12 
but further analysis did not identify a learning curve 
effect.13 However, other large multicentre prospective 
studies have not shown a significant difference in 
incidence of com plications or patient-reported outcomes 
between single-stage direct-to-implant and two-stage 
techniques,14 or between two-stage expander-implant 
reconstruction done with and without acellular dermal 
matrix.15 Although these findings are supportive of the 
technique, there remains the need for high-quality 
Research in context
Evidence before this study
At the start of this study in August, 2013, we searched 
MEDLINE, Embase, and the Cochrane database using the 
search terms for implant reconstruction—“[implant$; 
expander$; prosthe$]” AND “mesh [including ADM; acellular 
derma$; AlloDerm, SurgiMend, Strattice]”, for studies 
published between Jan 1, 2000, and Aug 1, 2013—to identify 
original papers and systematic reviews investigating the 
outcomes of mesh-assisted implant reconstruction. We 
identified eight systematic reviews and 61 primary studies, 
including one randomised controlled trial. All the systematic 
reviews were of low quality and at high risk of bias. The 
randomised clinical trial compared two-stage expander-
implant reconstruction with and without mesh. It was well 
designed and at low risk of bias, but was stopped prematurely 
because of problems with recruitment. The primary outcome 
was postoperative pain and pain during the expansion period, 
but not the safety of using mesh. An interim analysis 
suggested that there was unlikely to be a difference in pain 
scores between the treatment groups in the randomised 
controlled trial. The remaining studies comprised 
40 comparative studies and 20 case series, all of which were at 
high risk of bias.
We did another PubMed search in April, 2018, and identified 
one small randomised clinical trial that compared standard 
two-stage expander-implant reconstruction with 
mesh-assisted, single-stage, direct-to-implant breast 
reconstruction. The frequency of complications in the 
single-stage, mesh-assisted, direct-to-implant group was 
significantly higher than that in patients receiving two-stage 
expander implant reconstruction, and the study was stopped 
prematurely. A further small randomised clinical trial 
compared biological and synthetic mesh in single-stage, 
direct-to-implant breast reconstruction. Although this study 
provided evidence that a trial might be possible, it was 
underpowered and insufficiently well designed to produce 
meaningful results. Several small exploratory trials have 
compared different types of biological mesh. These studies did 
not show any differences between products, but were small 
and underpowered.
Added value of this study
This prospective cohort study of more than 2000 patients 
having immediate implant-based breast reconstruction in the 
UK provides high-quality, real-world data regarding the 
short-term safety outcomes of different implant-based 
techniques with and without mesh. The frequency of key 
complications, including implant loss, infection, re-admission, 
and re-operation for complications of reconstructive surgery, 
was much higher than anticipated; although adverse 
outcomes were associated with smoking and increased 
body-mass index, there was no association with the use or 
type of mesh in this non-randomised study. These findings 
support the need for a future pragmatic randomised clinical 
trial to determine the most clinical and cost-effective 
technique of implant-based breast reconstruction.
Implications of all the available evidence
Complications after immediate implant-based reconstruction 
with and without mesh are high, and patients should be 
carefully counselled regarding their surgical options. Surgeons 
should commit to robustly assessing mesh-assisted, 
implant-based breast reconstruction in the context of a well 
designed randomised clinical trial. Further work is needed to 
explore the most acceptable study design and test the 
feasibility of randomisation in a pilot randomised clinical trial. 
Urgent work will also be necessary to determine how the high 
incidences of complications shown in this study could be 
reduced.
Articles
256 www.thelancet.com/oncology   Vol 20   February 2019
evidence from a randomised study to support practice. 
A small randomised clinical trial16 that compared 
biological and synthetic mesh in single-stage 
direct-to-implant reconstruction was underpowered and 
insufficiently well designed to generate meaningful 
results.
There is therefore a need for high-quality research to 
establish the safety and effectiveness of mesh in 
immediate implant-based breast reconstruction, to 
determine what mesh should be recommended, and, as 
practice evolves, to determine if the implant should be 
placed on top of or underneath the pectoralis muscle.7
Randomised clinical trials are ideally needed, but 
randomised clinical trials in breast reconstruction are 
challenging because of patient and surgeon preference17 
and previous trials have closed prematurely because not 
enough patients were able to be recruited.18,19 Careful pre-
trial work is therefore needed to ensure that a future 
randomised clinical trial is well designed and addresses 
questions that are important to patients and the 
reconstructive community.
iBRA (implant Breast Reconstruction evAluation)20 is a 
four-phase study that aims to inform the feasibility, 
design, and conduct of a future trial in immediate implant-
based breast reconstruction. Results from phase 1 
(a national practice questionnaire to understand current 
practice) were previously reported.21,22 Here we report the 
primary endpoint for phase 2, a prospective multicentre 
national study to determine the short-term clinical 
outcomes of different approaches to immediate implant-
based breast reconstruction in the UK and inform the 
selection of comparators and sample size for a future 
randomised clinical trial.
Methods
Study design and participants
For this prospective, multicentre iBRA study, we invited 
all UK breast or plastic surgical units performing 
immediate implant-based breast recon struction to 
participate in the study, through the UK Trainee 
Collaborative Research Network and two professional 
associations, the Association of Breast Surgery and 
the British Association of Plastic Reconstructive and 
Aesthetic Surgeons. 81 centres participated in the study.
Women aged 16 years or older, who had a mastectomy 
and immediate implant-based breast reconstruction 
using any technique for malignancy or risk reduction at 
participating centres, were consecutively recruited to the 
study. Patients were excluded if they had reconstruction 
with an implant in combination with a tissue flap 
(eg, latissimus dorsi flap and implant), had delayed 
reconstruction, or had revisional surgery.
Ethics approval was not required, as defined by the HRA 
decision tool. The study involved the collection of clinical 
and patient-reported outcome data as routinely 
recommended by guidelines for good practice23 and 
outcomes assessed against these quality standards. 
Each participating centre was required to obtain local audit 
approvals and register the study before commencing study 
recruitment, consistent with the methods of previously 
reported multicentre prospective trainee collaborative 
studies. Patient consent was not required for routine 
clinical data collection, but patients provided written 
informed consent to receive patient-reported outcome 
questionnaires, in keeping with the methods employed in 
the UK National Mastectomy and Breast Reconstruction 
Audit.24 All data were recorded in an anonymised format 
on a secure web-based database, REDCap.25
Procedures
We prospectively identified eligible patients from clinics, 
multidisciplinary team meetings, and theatre lists. 
Simple demographic, comorbidity, and operative data 
were collected for each participant.
All patients had skin or nipple-sparing mastectomy 
followed by immediate implant-based breast recon-
struction. Implants or tissue expanders could be placed 
under the pectoralis muscle (subpectoral) with or without 
biological or synthetic mesh, or on top of the muscle 
(pre-pectoral) supported by mesh. Since one aim of the 
study was to explore current practice to inform a future 
trial, no restrictions were placed on the technique used, 
but details of the procedures done were recorded.
Participating surgeons did the procedures according to 
their routine practice. Mesh choice (biological or synthetic 
and the specific product used), implant selection 
(definitive fixed-volume implant, adjustable implant, or 
temporary tissue expander), and implant positioning (pre-
pectoral or sub-pectoral) were as per surgeon pref erence. 
Strategies to reduce infection (eg, use of laminar flow, 
glove change before implant insertion, and wound lavage) 
were as per local policy. Reconstructions were considered 
to be two-stage if a temporary expander was placed at the 
time of the initial mastectomy and a second procedure 
was planned to insert a definitive implant at a later date.
Precise details of the techniques used varied by surgeon, 
but broadly, for submuscular reconstructions, a tissue 
expander was inserted in a pocket created under the 
pectoralis muscle. Serratus fascia could be raised to 
provide complete expander coverage, or the lateral aspect 
of the expander could be left subcutaneous as per surgeon 
preference.
Sub-pectoral reconstruction with mesh involved 
releasing the lower boarder of the pectoralis muscle 
from the chest wall and suturing the mesh to the free 
edge of the muscle. A definitive fixed-volume implant, 
adjustable implant, or tissue expander was then inserted 
according to surgeon preference and the mesh either 
sutured at the level of the inframammary fold or tucked 
under the implant, depending on the product used. For 
dermal sling reconstruction, the pectoralis muscle was 
detached in a similar way and the lower mastectomy 
flap de-epithelialised and sutured to the free muscle 
edge to provide coverage of the lower pole of the 
For more on the HRA decision 
tool see http://www.hra-
decisiontools.org.uk/research
For more on REDCap see 
http://www.projectredcap.org/
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implant. It is not standard practice to use mesh in this 
procedure.
Finally, for pre-pectoral reconstruction, the pectoralis 
muscle was not disturbed, but a fixed-volume implant, 
adjustable implant, or temporary tissue expander 
completely or partially wrapped in mesh (depending on 
surgeon preference and product selection) was placed in 
the mastectomy cavity and sutured into place.
In all cases, perioperative and postoperative antibiotics 
and drains were used according to local policy or surgeon 
preference.
Complication and oncological data were collected by 
the clinical team at 30 days and 3 months after 
reconstruction by clinical or case-note review, or both, 
depending on when the patient returned for follow-up.
Participants were approached in the clinic or during 
their hospital stay to obtain consent for patient-reported 
outcome assessment at 3 months after surgery. The 
patient-reported outcome was a modified version of 
the 3-month questionnaire used in the UK National 
Mastectomy and Breast Reconstruction Audit (NMBRA) 
and included patient self-report of complications 
occurring in the 3 months after surgery.24 Questionnaires 
were sent centrally by post or e-mail, depending on 
patient preference, with a reminder sent 1 month after 
the initial questionnaire if no response was received. 
Patient satisfaction was also assessed at 18 months after 
surgery.20 Analyses are ongoing and these results will be 
reported elsewhere.
Outcomes
On the basis of published national quality standards for 
breast reconstruction derived from the NMBRA,23 we 
prespecified four key outcomes to assess the short-term 
safety of different approaches to immediate implant-
based breast reconstruction.20 We chose these outcomes 
because it was anticipated that a safety outcome might be 
the primary endpoint of a future trial and equivalence in 
a non-randomised study was important in informing the 
selection of potential comparators for this study. The 
outcomes were defined implant loss (the unplanned 
removal or loss of the implant as a result of infection or 
other complication), infection (the presence of a hot, red 
breast requiring treatment with antibiotics, surgery, or 
both), re-admission (any unplanned re-admission to 
hospital after discharge for any complication of surgery), 
and reoperation (any return to the operating theatre for a 
complication within 3 months of the reconstruction 
procedure). Any implant loss, infection, re-admission, or 
re-operation occurring at any timepoint within the first 
3 months of the initial reconstruction that was assessed 
by clinical review or patient self-report was considered an 
event and included in the analysis.
We identified potential risk factors for each of these key 
outcomes using a prespecified exploratory risk-factor 
analysis. We identified specific variables of interest a 
priori from the published literature and expert opinion, 
and included the following patient-related and procedure-
related factors: age, body-mass index (BMI), smoking 
(current smokers vs others), previous radiotherapy to the 
ipsilateral breast (yes vs no), receipt of neoadjuvant 
chemotherapy (yes vs no), bilateral surgery (yes vs no), 
mastectomy type (nipple-sparing vs other mas tectomy 
types), type of implant or expander used (fixed-volume vs 
adjustable implants or expanders), and type of immediate 
implant-based breast reconstruction performed. We 
classified reconstruction procedures according to the 
mode of lower pole coverage as being: submuscular or 
subfascial without mesh; dermal-sling procedures using 
the patient’s own tissue; biological mesh-assisted 
(including acellular dermal matrix and non-dermal 
biological products); synthetic mesh-assisted; pre-pectoral 
if the implant was placed on top of the pectoralis muscle 
with or without mesh; and other if a combination of 
techniques was used (eg, dermal sling and mesh).
For quality assurance purposes, the principal investigator 
at each participating site was asked to independently 
validate the primary outcomes for all study participants at 
3 months and to check complete case ascertainment.
Statistical analysis
Because we aimed to inform the design of a future 
randomised clinical trial, the study was powered to 
establish parameters required for a sample size 
calculation and to inform further aspects of trial design, 
such as entry criteria for the future trial.
At the time of study design, four clinical outcomes 
(implant loss, re-admission, re-operation, and infection) 
were considered to be potential primary outcomes in a 
randomised controlled trial, and a wide range of 
treatment approaches for immediate implant-based 
breast reconstruction were routinely offered.22 A large 
sample was therefore required to estimate, with 
reasonable precision, the incidence of the four clinical 
outcomes of interest (implant loss, re-admission, re-
operation, and infection) within treatment approaches, 
and to determine how implant procedures are performed 
and any variation in patient selection for each of these 
approaches. We therefore planned to recruit as many 
patients as possible and follow all patients to 3 months. 
The NMBRA24 observed that 9% of patients who had 
immediate implant-based breast reconstruction reported 
implant loss at 3 months. When designing a full trial, 
establishing this proportion with reasonable precision 
would be required. A sample size of 197 participants 
would allow a two-sided 95% CI for a single proportion, 
assumed to be 0·09, extending from 0·05 to 0·13, using 
the large sample normal approximation. Allowing for the 
15% loss to follow-up at 3 months reported in the 
NMBRA, an analysis of implant loss at 3 months required 
at least 235 patients to be recruited to inform a future 
trial with implant loss as a primary outcome. To 
determine how implant procedures are performed, 
centres participating in a national practice questionnaire 
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(n=81)21,22 were eligible to participate. All centres were 
eligible because each unit was expected to vary in 
caseload and perform a relatively small number of 
procedures (4–40 per year). All analyses are based on the 
number of patients, not the number of implants.
We did the analysis according to a prespecified statistical 
analysis plan approved by the trial steering group. We 
used simple summary statistics to describe demographic, 
procedure, process, and outcome data, overall and 
by procedure type. We summarised categorical data by 
counts and percentages, and continuous data by median, 
upper and lower quartiles, and range. We did no formal 
statistical testing.
We established the proportion and 95% CI of patients 
for each of the four key clinical outcomes to compare our 
findings against those reported in the NMBRA24 and 
published national quality standards.23
We did a prespecified risk-factor analysis using 
multivariable logistic regression. Variables of interest 
included patient age, BMI, smoking status, previous 
radiotherapy to the ipsilateral breast, receipt of neo-
adjuvant chemotherapy, bilateral surgery, nipple-sparing 
versus other mastectomy types, use of fixed-volume versus 
adjustable implants or expanders, and type of immediate 
implant-based breast reconstruction performed.
Data were considered missing at random (appendix p 2) 
and therefore no missing data items were imputed. We 
did a complete case analysis. We considered this 
approach as unlikely to lead to bias because all included 
risk factors were measured once per patient.26 We 
checked linearity for continuous variables for all 
four logistic models using locally estimated scatterplot 
smoothing (LOESS) smoothed-line plots. These checks 
showed no obvious evidence of non-linearity for the 
effects of the three continuous variables. We considered 
a p value of less than 0·05 to be statistically significant, 
and made no adjustments for multiplicity. Instead, we 
took into consideration relevant results from other 
studies in the interpretation of results, and emphasise 
the exploratory nature of this study. We used SAS 
(version 9.3) for all analyses.
This study was registered as an International Standard 
Randomised Controlled Trial, number ISRCTN37664281, 
and the protocol was published in 2016.20
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Feb 1, 2014, and June 30, 2016, 2217 records 
were entered onto the REDCap database. Of these, 
109 (5%) were excluded: 34 patients had surgery outside 
the study period, 22 records did not include an operation 
date, 50 records provided no information regarding the 
type of surgery performed, and three patients did not 
have an immediate implant-based breast reconstruction. 
2108 patients were therefore included in the analysis 
(figure). The median recruitment per unit was 14 cases 
(IQR 6–39). Further details about unit recruitment are in 
the appendix (pp 3–7).
Biological mesh-assisted reconstruction was the most 
commonly performed procedure, with 1133 (54%) of 
2108 patients undergoing this technique. Fewer patients 
had synthetic mesh-assisted immediate implant-based 
breast reconstruction (243 [12%]), and 181 (9%) received 
traditional subpectoral reconstruction without mesh. 
Subpectoral reconstruction with a dermal sling was done 
in approximately a fifth of patients (440 [21%]) and pre-
pectoral reconstruction with mesh (42 [2%]) was done in 
the latter stages of the study. 64 (3%) patients received a 
combination of techniques (eg, subpectoral recon-
struction with dermal sling and mesh) and for 15 (7%) 
2217 patients entered into REDCap database
56 excluded
 34 surgery outside study period
 22 operation date not recorded
2161 had surgery during study period
53 excluded
 3 no immediate implant-based breast 
 reconstruction
 50 procedure not reported
2108 included in study
 181 submuscular or subfascial without mesh
 440 dermal sling
 1133 biological mesh
 243 synthetic mesh
 42 pre-pectoral
 64 other
 15 not known
27 lost to follow-up
2081 with 3-month follow-up included in 3-month 
 outcome analysis
 180 submuscular or subfascial without mesh
 436 dermal sling
 1121 biological mesh
 236 synthetic mesh
 42 pre-pectoral
 63 other
Figure: Trial profile
For patients with two implant-based reconstructions in which technique differed 
by breast (n=10), these patients are summarised in both groups, depending on 
the approach used, and once in the total. Variations of approaches per breast 
within patient were: biological mesh and dermal sling (n=3), biological mesh 
and synthetic mesh (n=1), dermal sling and submuscular or subfascial (n=4), 
other and submuscular or subfascial (n=1), and other and synthetic mesh (n=1).
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All patients* 
(N=2108)
Submuscular or 
subfascial† 
(n=181)
Dermal sling 
(n=440)
Biological mesh 
(n=1133)
Synthetic mesh 
(n=243)
Pre-pectoral 
(n=42)
Other 
(n=64)‡
Not known 
(n=15)
Age, years
Median (IQR; range) 49 (43–57; 
16–83);
49 (43–56; 
16–80)
51 (45–59; 
24–81)
49 (42–56; 
20–80)
50 (43–58; 
20–83)
48 (38–52; 
19–73)
49 (43–58; 
23–74)
46 (46–52; 
39–63)
Not known 13 (<1%) 0 2 (<1%) 4 (<1%) 1 (<1%) 0 0 6 (40%)
Body-mass index, kg/m²
Median (IQR; range) 24·8 (22·3–28·2; 
14·4–54·0)
24·0 (21·8–27·7; 
17–51·6)
28·0 (24·8–32·2; 
18·3–54·0)
24·0 (21·9–26·9; 
14·4–44·5)
24·8 (22·1–28·0; 
17·3–42·6)
23·8 (22·2–27·1; 
18·7–36·0)
27·6 (23·8–31·1; 
18·0–40·0)
23·8 (23·4–26·5; 
18·8–32·2)
Not obese (BMI <30 kg/m2) 1613 (77%) 133 (73%) 247 (56%) 976 (86%) 184 (76%) 33 (79%) 44 (69%) 4 (27%)
Obese (BMI ≥30 kg/m²) 367 (17%) 34 (19%) 163 (37%) 107 (9%) 36 (15%) 9 (21%) 19 (30%) 1 (7%)
Not known 128 (6%) 14 (8%) 30 (7%) 50 (4%) 23 (9%) 0 1 (1%) 10 (67%)
Smoking status
Non-smoker 1626 (77%) 137 (76%) 335 (76%) 881 (78%) 193 (79%) 31 (74%) 52 (81%) 6 (40%)
Ex-smoker (stopped more than 
6 weeks previously)
231 (11%) 19 (10%) 54 (12%) 123 (11%) 22 (9%) 8 (19%) 5 (8%) 0
Current smoker 206 (10%) 22 (12%) 42 (10%) 111 (10%) 26 (11%) 2 (5%) 4 (6%) 0
Nicotine replacement 10 (<1%) 0 3 (1%) 5 (<1%) 2 (1%) 0 0 0
Not known 35 (2%) 3 (2%) 6 (1%) 13 (1%) 0 1 (2%) 3 (5%) 9 (60%)
Diabetes
Yes 54 (3%) 4 (2%) 21 (5%) 17 (2%) 9 (4%) 0 3 (5%) 0
No 2013 (95%) 174 (96%) 408 (93%) 1099 (97%) 232 (95%) 41 (98%) 61 (95%) 8 (53%)
Not known 41 (2%) 3 (2%) 11 (2%) 17 (2%) 2 (1%) 1 (2%) 0 7 (47%)
Previous radiotherapy to ipsilateral breast
Yes 139 (7%) 14 (8%) 26 (6%) 76 (7%) 17 (7%) 2 (5%) 5 (8%) 1 (7%)
No 1953 (95%) 167 (92%) 413 (94%) 1052 (93%) 223 (92%) 40 (95%) 59 (92%) 7 (47%)
Not known 16 (2%) 0 1 (<1%) 5 (<1%) 3 (1%) 0 0 7 (47%)
Neoadjuvant chemotherapy
Yes 226 (11%) 28 (15%) 57 (13%) 111 (10%) 19 (8%) 1 (2%) 8 (13%) 2 (13%)
No 1853 (88%) 150 (83%) 381 (87%) 1006 (89%) 221 (91%) 41 (98%) 56 (88%) 7 (47%)
Not known 29 (1%) 3 (2%) 2 (<1%) 16 (1%) 3 (1%) 0 0 6 (40%)
Neoadjuvant endocrine therapy
Yes 78 (4%) 11 (6%) 21 (5%) 37 (3%) 8 (3%) 1 (2%) 2 (3%) 1 (7%)
No 1999 (95%) 167 (92%) 415 (94%) 1079 (95%) 233 (96%) 41 (98%) 61 (95%) 9 (60%)
Not known 31 (1%) 3 (2%) 4 (1%) 17 (2%) 2 (1%) 0 1 (2%) 5 (33%)
Previous surgery to ipsilateral breast
Yes 654 (31%) 61 (34%) 113 (26%) 371 (33%) 80 (33%) 8 (19%) 23 (36%) 4 (27%)
No 1434 (68%) 119 (66%) 322 (75%) 755 (67%) 162 (67%) 34 (81%) 41 (64%) 5 (33%)
Not known 20 (1%) 1 (1%) 5 (1%) 7 (<1%) 1 (<1%) 0 0 6 (40%)
Type of previous surgery(s) received
Wide local excision 375 (57%) 29 (48%) 60 (53%) 218 (59%) 49 (61%) 3 (38%) 16 (70%) 3 (75%)
With previous radiotherapy 108 (29%) 8 (28%) 17 (28%) 62 (28%) 15 (31%) 0 5 (31%) 1 (33%)
Without previous radiotherapy 265 (71%) 21 (72%) 43 (72%) 155 (71%) 33 (69%) 3 (100%) 11 (69%) 2 (67%)
Not known 2 (<1%) 0 0 1 (<1%) 1 (2%) 0 0 0
Sentinel node biopsy 299 (46%) 27 (44%) 48 (42%) 178 (48%) 31 (39%) 6 (75%) 10 (43%) 1 (25%)
Augmentation 49 (7%) 3 (5%) 5 (4%) 32 (9%) 6 (8%) 1 (13%) 2 (9%) 0
Reduction 28 (4%) 1 (2%) 5 (4%) 13 (4%) 6 (8%) 2 (25%) 3 (13%) 0
Other 116 (18%) 22 (36%) 19 (17%) 63 (17%) 14 (18%) 0 2 (9%) 0
Data are n (%) or median (IQR; range). Seven (<1%) of 2108 patients had missing data for all reported previous or neoadjuvant treatments. *For patients with two implant-based reconstructions in which technique 
differed by breast (n=10), these patients are summarised in both applicable columns, depending on the method used, and once in the total column. Variations of approaches per breast within patient were 
biological mesh and dermal sling (n=3), biological mesh and synthetic mesh (n=1), dermal sling and submuscular or subfascial (n=4), other and submuscular or subfascial (n=1), and other and synthetic mesh (n=1). 
†No mesh. 1261 (60%) patients reported no previous or neoadjuvant treatments. ‡Could include a combination of techniques that could include or not include mesh.
Table 1: Patient demographics, by type of implant-based reconstruction
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All patients* 
(N=2108)
Submuscular or 
subfascial† 
(n=181)
Dermal sling 
(n=440)
Biological mesh 
(n=1133)
Synthetic 
mesh (n=243)
Pre-pectoral 
(n=42)
Other 
(n=64)
Not known 
(n=15)
ASA grade
1 1246 (59%) 89 (49%) 206 (47%) 736 (65%) 155 (64%) 25 (60%) 36 (56%) 5 (33%)
2 783 (37%) 82 (45%) 213 (48%) 371 (33%) 80 (33%) 15 (36%) 25 (39%) 1 (7%)
3 57 (3%) 8 (4%) 15 (3%) 22 (2%) 7 (3%) 2 (5%) 2 (3%) 1 (7%)
4 0 0 0 0 0 0 0 0
Not known 22 (1%) 2 (1%) 6 (1%) 4 (<1%) 1 (<1%) 0 1 (2%) 8 (53%)
Laterality
Bilateral 547 (26%) 141 (78%) 299 (68%) 866 (76%) 174 (72%) 21 (50%) 45 (70%) 15 (100%)
Unilateral 1561 (74%) 40 (22%) 141 (32%) 267 (24%) 69 (28%) 21 (50%) 19 (30%) 0
Indication‡§
Malignancy only 1505 (71%) 137 (76%) 284 (65%) 835 (74%) 173 (71%) 20 (48%) 43 (67%) 13 (87%)
Risk reduction only 411 (19%) 27 (15%) 94 (21%) 209 (18%) 48 (20%) 18 (43%) 17 (27%) 0
Malignancy and contralateral 
risk-reducing surgery
188 (9%) 17 (9%) 62 (14%) 88 (8%) 22 (9%) 4 (10%) 3 (5%) 0
Not known 4 (<1%) 0 0 1 (<1%) 0 0 1 (2%) 2 (13%)
Planned procedure‡¶
Single-stage reconstruction 1638 (78%) 77 (43%) 301 (68%) 969 (86%) 200 (82%) 36 (86%) 52 (81%) 7 (47%)
Two-stage reconstruction 453 (21%) 100 (55%) 134 (30%) 159 (14%) 42 (17%) 6 (14%) 12 (19%) 4 (27%)
Different approach per breast 12 (1%) 4 (2%) 5 (1%) 4 (<1%) 1 (<1%) 0 0 0
Not known 5 (<1%) 0 0 1 (<1%) 0 0 0 4 (27%)
Type of mastectomy‡||**
Skin-sparing 1161 (55%) 117 (65%) 96 (22%) 756 (67%) 149 (61%) 15 (36%) 24 (38%) 5 (33%)
Skin and nipple-sparing 486 (23%) 41 (23%) 21 (5%) 308 (27%) 81 (33%) 22 (52%) 15 (23%) 1 (7%)
Reduction pattern 398 (19%) 7 (4%) 308 (70%) 51 (5%) 6 (2%) 5 (12%) 22 (34%) 0
Other 18 (1%) 9 (5%) 3 (1%) 3 (<1%) 1 (<1%) 0 2 (3%) 0
Different type per breast 32 (2%)§ 7 (4%) 12 (3%) 13 (1%) 4 (2%) 0 1 (2%) 0
Not known 13 (1%) 0 0 2 (<1%) 2 (1%) 0 0 9 (60%)
Incision††
Peri-areolar 127 (6%) 10 (6%) 3 (1%) 90 (8%) 16 (7%) 3 (7%) 5 (8%) 0
Lateral 159 (8%) 13 (7%) 2 (<1%) 108 (10%) 29 (12%) 5 (12%) 2 (3%) 0
Inframammary 230 (11%) 20 (11%) 4 (1%) 149 (13%) 40 (16%) 13 (31%) 5 (8%) 1 (7%)
Elliptical removing NAC 936 (44%) 106 (59%) 13 (3%) 665 (59%) 123 (51%) 11 (26%) 17 (26%) 2 (13%)
Wise pattern 541 (26%) 11 (6%) 403 (92%) 77 (7%) 13 (5%) 7 (17%) 31 (48%) 1 (7%)
Other 78 (4%) 16 (9%) 6 (1%) 36 (3%) 16 (7%) 2 (5%) 3 (5%) 0
Different approaches per breast 19 (1%)¶ 5 (3%) 6 (1%) 7 (1%) 3 (1%) 1 (2%) 1 (2%) 0
Not known 18 (1%) 0 3 (1%) 1 (<1%) 3 (1%) 0 0 11 (73%)
Mastectomy weight, grams ‡††
Median (IQR; range) 390 
(260–583; 
39–2300)
321 
(208–456; 
68–2300)
665 
(492–915; 
53–2260)
327 
(229–476; 
39–1480)
383 
(264–540; 
83–2200)
310 
(230–527; 
75–1544)
544 
(332–790; 
166–1505)
280 
(280–280) 
(280–280)
Not known 90 (4%) 17 (9%) 13 (3%) 31 (3%) 9 (4%) 2 (5%) 5 (8%) 14 (93%)
Prosthesis used‡§§
Fixed-volume implant 1235 (59%) 50 (28%) 210 (48%) 737 (65%) 166 (68%) 36 (86%) 39 (61%) 2 (13%)
Combined expander or implant 466 (22%)** 50 (28%) 102 (23%) 250 (22%) 46 (19%) 1 (2%) 18 (28%) 1 (7%)
Expander 383 (18%) 80 (44%) 125 (28%) 140 (12%) 29 (12%) 4 (10%) 7 (11%) 0
Different approaches per breast 4 (<1%) 0 0 4 (<1%) 1 (<1%) 0 0 0
Not known 20 (1%) 1 (<1%) 3 (1%) 2 (<1%) 1 (<1%) 1 (2%) 0 12 (80%)
Axillary surgery‡¶¶
None 585 (28%) 46 (25%) 121 (28%) 315 (28%) 67 (28%) 20 (48%) 21 (33%) 0
SNB 881 (42%) 64 (35%) 177 (40%) 495 (44%) 106 (44%) 11 (26%) 23 (36%) 5 (33%)
Axillary sample 23 (1%) 5 (3%) 1 (<1%) 13 (1%) 3 (1%) 0 0 1 (7%)
(Table 2 continues on next page)
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patients, details of the technique were not reported. 
Strattice (LifeCell, Brachburg, NJ, USA) or SurgiMend 
(Integra LifeSciences) were used in 1215 (66%) of the 
1831 mesh-assisted procedures, but in total, 14 different 
products were used during the course of the study (Artea, 
BioDesign, Braxon, Cellis, Meso Biomatrix, Native, 
Protexa, Silk, Strattice, SurgiMend, TIGF, TiLOOP, 
Veritas, and XCM), with an increasing variety of products 
used as the study progressed (data not shown).
The median age of study participants was 49 years 
(43–57; table 1). Median BMI was at the upper end of the 
normal range (24·8 kg/m; IQR 22·3–28·2), and was 
highest overall in patients who had dermal sling 
reconstruction (table 1). 206 (10%) of 2108 patients were 
current smokers and 139 (7%) had received previous 
radiotherapy to the ipsilateral breast (table 1). The 
2108 study participants had 2655 implant-based 
reconstructive procedures. 411 (19%) patients had risk-
reducing mastectomies and 1505 (72%) had malignancy 
only. Of the 547 (26%) patients having bilateral surgery, 
188 (34%) had a contralateral risk-reducing mastectomy 
at the time of their index cancer operation (table 2).
A one-stage reconstruction was planned in 1650 
(78%) patients, and 1239 (59%) had a definitive fixed-
volume implant placed at the time of their surgery. 
Two-stage reconstruction with tissue expanders or 
expandable implants was more common in patients 
having traditional submuscular procedures without mesh 
and those having dermal sling reconstruction than in 
those having other procedure types (table 2). Skin and 
nipple-sparing reconstruction was done in nearly a quarter 
of cases (table 2).
Approximately a third of the 1693 patients having 
mastectomy and immediate implant-based breast 
reconstruction for malignancy were recommended 
chemo therapy or radiotherapy after their reconstruction 
(table 3). This recommendation did not appear to be 
related to the type of procedure performed, although 
more patients having standard subpectoral reconstruction 
without mesh were recommended for radiotherapy than 
were patients having other procedure types (table 3).
Of the 2108 patients recruited, 2081 (99%) were 
followed up to 3 months (median follow-up 3 months, 
IQR 3–3). The clinical outcomes of interest are 
summarised in table 4 overall, and split by type of 
immediate implant-based breast reconstruction 
procedure. NMBRA data and quality standards for 
breast reconstruction23 are also included for comparison. 
Implant loss was experienced by 182 (9%) of 
2081 patients followed up at 3 months, which is 
equivalent to the NMBRA published data (9%) but 
higher than National Quality Standards (<5%). 
522 (25%) patients had a postoperative infection 
requiring treatment, and 372 (18%) patients were 
All patients* 
(N=2108)
Submuscular or 
subfascial† 
(n=181)
Dermal sling 
(n=440)
Biological mesh 
(n=1133)
Synthetic 
mesh (n=243)
Pre-pectoral 
(n=42)
Other 
(n=64)
Not known 
(n=15)
(Continued from previous page)
Axillary clearance 226 (11%) 29 (16%) 48 (11%) 112 (10%) 24 (10%) 4 (10%) 9 (14%) 0
SNB and ANC 32 (2%) 3 (2%) 9 (2%) 15 (1%) 4 (2%) 0 1 (2%) 0
Previous axillary staging 164 (8%) 16 (9%) 23 (5%) 99 (9%) 16 (7%) 3 (7%) 7 (11%) 0
Different approach per breast 186 (9%) 18 (10%) 60 (14%) 83 (7%) 23 (9%) 4 (10%) 3 (5%) 0
Not known (%) 11 (<1%) 0 1 (<1%) 1 (<1%) 0 0 0 9 (60%)
Operative time, min
Median (IQR; range) 180 (147–210; 
60–570)
160 (130–195; 
60–380)
186 (150–240; 
62–530)
180 (150–210; 
69–570)
165 (135–187; 
70–410)
180 (147–240; 
68–380)
180 
(150–246; 
60–480)
149 (118–180; 
118–180)
Not known 195 (9%) 24 (13%) 37 (8%) 97 (9%) 4 (2%) 17 (40%) 3 (5%) 13 (87%)
Data are n (%), unless stated otherwise. ASA=American Society of Anesthesiologists. NAC=neoadjuvant chemotherapy. SNB=sentinel node biopsy. ANC=axillary node clearance. *For patients with two implant-based 
reconstructions in which method differed by breast (n=10), these patients are summarised in both applicable columns, depending on the method used, and once in the total column. Variations of approaches 
per breast within patient were biological mesh and dermal sling (n=3), biological mesh and synthetic mesh (n=1), dermal sling and submuscular or subfascial (n=4), other and submuscular or subfascial (n=1), other 
and synthetic mesh (n=1). †No mesh. ‡Variable collected on a per-breast basis; for patients with two implant-based reconstructions, with data for one breast and not the other, that patient is classified according to 
the non-missing data as indicated in the applicable footnote. §Six patients classified according to non-missing data. ¶One patient classified according to non-missing data. ||Five patients classified according to 
non-missing data. **Combinations of type of mastectomy within patients with two implant-based reconstructions with different types per breast were skin-sparing mastectomy and skin and nipple-preserving 
mastectomy (n=15), skin-sparing mastectomy and reduction (Wise) pattern (n=7), skin-sparing mastectomy and other (n=3), skin and nipple preserving and reduction (Wise) pattern (n=2), skin and nipple 
preserving and other (n=4), reduction (Wise) pattern and other (n=1). ††Six patients classified according to non-missing data. Combinations of location of incision within patients with two implant-based 
reconstructions with different types per breast were elliptical removing NAC and inframammary (n=1), elliptical removing NAC and lateral (n=4), elliptical removing NAC and other (n=3), elliptical removing NAC and 
peri-areolar (nipple preserving; n=3), elliptical removing NAC and Wise-pattern (n=1), inframammary and lateral (n=1), inframammary and other (n=2), inframammary and peri-areolar (nipple preserving; n=1), 
lateral and peri-areolar (nipple preserving; n=1), other and Wise pattern (n=2). ††19 patients classified according to non-missing data. When two patients had two implant-based reconstructions with mastectomy 
weight data for both breasts (n=511), the average weight is given. The difference in weight between breasts varied from 0 g to 463 g (median 40 g). §§Seven patients classified according to non-missing data . 
Combinations of breast prosthesis used within patients with two implant-based reconstructions with different types per breast were combined implant (Beckers) and fixed-volume implant (n=1), and fixed-volume 
implant and temporary expander (n=3). ¶¶Four patients classified according to non-missing data. Combinations of axillary surgery within patients with two implant-based reconstructions with different surgeries 
per breast were axillary clearance and none (n=41), axillary clearance and previous staging axillary surgery (n=1), axillary clearance and sentinel node biopsy (n=10), axillary sample and none (n=6), none and previous 
staging axillary surgery (n=32), none and sentinel node biopsy and immediate clearance (n=2), none and sentinel node biopsy (n=46), and sentinel node biopsy and previous staging axillary surgery (n=1).
Table 2: Operative details, by type of implant-based reconstruction
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re-admitted for a complication after their reconstruction 
within 3 months. Both of these findings are consistent 
with results from the NMBRA23 and greater than the 
National Quality Standards (table 4). However, the 
proportion of patients requiring reoperation was greater 
than that in the NMBRA, with 370 (18%) patients in this 
cohort requiring further surgery for complications after 
their recon struction procedure (table 4).
All patients* 
(N=1693)
Submuscular or 
subfascial† (n=154)
Dermal sling 
(n=340)
Biological mesh 
(n=922)
Synthetic mesh 
(n=194)
Pre-pectoral 
(n=24)
Other 
(n=46)
Not known 
(n=13)
Laterality
Unilateral malignancy 1633 (96%) 147 (95%) 329 (97%) 896 (97%) 184 (95%) 20 (83%) 44 (96%) 13 (100%)
Bilateral malignancy 60 (4%) 7 (5%) 11 (3%) 26 (3%) 10 (5%) 4 (17%) 2 (4%) 0
Invasive status
Invasive 1223 (72%) 113 (73%) 244 (72%) 656 (71%) 144 (74%) 22 (92%) 34 (74%) 10 (77%)
Ductal carcinoma in situ 363 (21%) 25 (16%) 76 (22%) 214 (23%) 39 (20%) 1 (4%) 7 (15%) 1 (8%)
Different status per breast 11 (1%) 1 (1%) 1 (<1%) 8 (1%) 1 (1%) 0 0 0
Not known 96 (6%) 15 (10%) 19 (6%) 44 (5%) 10 (5%) 1 (4%) 5 (11%) 2 (15%)
Grade
Low grade or well 
differentiated
131 (8%) 7 (5%) 20 (6%) 81 (9%) 15 (8%) 2 (8%) 3 (7%) 3 (23%)
Intermediate grade or 
moderately differentiated
653 (39%) 69 (45%) 137 (40%) 341 (37%) 75 (39%) 11 (46%) 15 (33%) 5 (38%)
High grade or poorly 
differentiated
418 (25%) 35 (23%) 80 (24%) 230 (25%) 50 (26%) 6 (25%) 15 (33%) 2 (15%)
Different per breast 14 (1%) 0 4 (1%) 5 (<1%) 1 (1%) 3 (13%) 1 (2%) 0
Not known 477 (28%) 43 (28%) 99 (29%) 265 (29%) 53 (27%) 2 (8%) 12 (26%) 3 (23%)
Size of lesion, mm
Median (IQR; range)‡ 21 (12–35; 0–750) 20 (16–50; 0–114) 23 (12–39; 0–750) 20 (12–31; 
0–125)
28 (14–42; 
0–120)
20 (14–36; 3–80) 20 (13–36; 
0–150)
14 (7–19; 0–65)
Not known 480 (28%) 43 (28%) 98 (29%) 265 (29%) 54 (28%) 2 (8%) 15 (33%) 3 (23%)
Number of involved nodes
Number (IQR; range) 0 (0–1; 0–54)§ 0 (0–1; 0–22) 0 (0–1; 0–28) 0 (0–0; 0–32) 0 (0–1; 0–54) 0 (0–1; 0–5) 0 (0–1; 0–25) 0 (0–1; 0–0)
Not known 113 (7%) 15 (10%) 21 (6%) 53 (6%) 12 (6%) 1 (4%) 8 (17%) 3 (23%)
Planned ANC for node-positive patients
Node-positive 425 (25%) 47 (31%) 91 (27%) 213 (23%) 59 (30%) 6 (25%) 10 (22%) 0
 Yes planned ANC 193 (48%)¶ 28 (62%) 34 (37%) 99 (50%) 29 (52%) 1 (17%) 2 (25%) 0
 No planned ANC 206 (52%)¶ 17 (38%) 53 (58%) 98 (50%) 27 (48%) 5 (83%) 6 (75%) 0
 Not known 26 (6%) 2 (4%) 4 (4%) 16 (8%) 3 (5%) 0 2 (20%) 0
Multidisciplinary team treatment recommendation
Adjuvant chemotherapy
Yes 562 (33%) 65 (42%) 103 (30%) 299 (32%) 71 (37%) 10 (42%) 13 (28%) 1 (8%)
No 1002 (59%) 73 (47%) 212 (62%) 561 (61%) 112 (58%) 13 (54%) 26 (57%) 5 (38%)
Not known 129 (8%) 16 (10%) 25 (7%) 62 (7%) 11 (6%) 1 (4%) 7 (15%) 7 (54%)
Adjuvant radiotherapy
Yes 495 (29%) 71 (46%) 101 (30%) 246 (27%) 62 (32%) 3 (13%) 11 (24%) 1 (8%)
No 1055 (62%) 63 (41%) 210 (62%) 613 (66%) 118 (61%) 18 (75%) 28 (61%) 5 (38%)
One breast only|| 17 (1%) 2 (1%) 4 (1%) 6 (1%) 3 (2%) 2 (8%) 0 0
Not known 126 (7%) 18 (12%) 25 (7%) 57 (6%) 11 (6%) 1 (4%) 7 (15%) 7 (54%)
Adjuvant endocrine therapy
Yes 1081 (64%) 95 (62%) 209 (61%) 597 (65%) 126 (65%) 19 (79%) 29 (63%) 6 (46%)
No 491 (29%) 40 (26%) 106 (31%) 275 (30%) 56 (29%) 4 (17%) 10 (22%) 0
Not known 121 (7%) 19 (12%) 25 (7%) 50 (5%) 12 (6%) 1 (4%) 7 (15%) 7 (54%)
Data are n (%), unless otherwise stated. ANC=axillary node clearance. *Includes data for 13 patients for whom mode of lower pole coverage was missing, who are not counted in the applicable type column. 
†No mesh. ‡When two patients have two malignant breasts with lesion size data for both breasts (n=38), the average lesion size is given. Size of lesions between breasts within these patients varied from 0 mm to 
70 mm (median 10). §When two patients have two malignant breasts and there were data about the number of lymph nodes involved for both breasts (n=53), the average number of nodes is given. The number of 
lymph nodes between breasts varied from 0 to 15 (median 0). ¶When two patients had two malignant breasts with planned axillary clearance data available for one breast, patients are classified according to the 
breast for which there are data (n=12 yes, n=9 no). ||When both breasts were operated for cancer but only one side needed radiotherapy.
Table 3: Postoperative data for patients having mastectomy for oncological indications
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Using exploratory multivariable logistic regression, we 
identified an apparent association between body-mass 
index and smoking with all four clinical outcomes (table 5). 
This analysis also identified an apparent association 
between infection and previous radiotherapy, and between 
reoperation and operative time. Age, neoadjuvant chemo-
therapy, bilateral surgery, indication for surgery, nipple-
sparing procedures, insertion of a definitive fixed-volume 
implant, and type of recon struction performed were not 
significant risk factors for any of the key safety outcomes 
(table 5). Details of the number of events for each risk 
factor are shown in the appendix (p 8).
Discussion
This national, multicentre, prospective cohort study of 
2108 patients having immediate implant-based breast 
reconstruction in 81 centres across the UK shows that the 
short-term clinical outcomes of immediate implant-
based breast reconstruction fall far short of the published 
aspirational quality standards for immediate breast 
reconstruction,23 and have not improved in the 10 years 
since the NMBRA.24 Despite recently published evidence 
showing increased frequency of complications in mesh-
assisted immediate implant-based breast reconstruction,11 
there was no association between type of mesh and short-
term safety outcomes in exploratory regression analyses 
of this large, non-randomised study. The optimum 
technique for immediate implant-based breast recon-
struction is therefore unknown and more comparative 
data are needed. To truly answer this important question, 
a large-scale, pragmatic, randomised controlled trial will 
be required to identify the most clinically and cost-
effective approach to immediate implant-based breast 
reconstruction, and provide information to inform 
clinical and health policy decisions.
Despite insufficient high-quality evidence, mesh-
assisted, single-stage, direct-to-implant reconstruction 
using fixed-volume or adjustable implants has become 
the most widely used procedure in the UK,22 with less 
than 10% of patients undergoing traditional two-stage 
expander-implant procedures. This widespread adoption 
of mesh suggests that a randomised controlled trial 
attempting to compare single-stage, direct-to-implant 
reconstruction with mesh and the standard two-stage 
techniques would be difficult because of surgeon 
preference. However, our study shows little difference in 
the short-term clinical outcomes of biological and 
synthetic mesh-assisted immediate implant-based breast 
reconstruction, and has highlighted the large number of 
products in current use. Pre-pectoral reconstruction was 
done only in a small number of patients in this study, 
although it is gaining popularity.7 Despite the challenges 
associated with a randomised clinical trial in breast 
reconstruction, methods have been developed and 
successfully used to overcome these issues and support 
surgeons to recruit patients into trials of very different 
types of procedures, in which patient and surgeon 
preferences might be strong.27
Although the type of reconstructive technique used 
does not appear to affect short-term safety outcomes, 
patient factors such as increased BMI and current 
smoking seemed to be associated with increased risks of 
implant loss, infection, re-admission, and reoperation. 
Additionally, these results indicate that previous radio-
therapy might be associated with a modest increase in 
the odds of developing a postoperative infection. 
Although this analysis was exploratory in nature, these 
results highlight the importance of careful patient 
selection and providing patients at high risk with accurate 
information about the likelihood of postoperative 
complications, to allow them to make better informed 
decisions. Operative time was another factor potentially 
associated with increased risk of some major 
complications, particularly reoperation. However, the 
effects of measures to reduce operating time (eg, dual-
surgeon operating for bilateral cancer, or doing a 
contralateral risk-reducing mastectomy in patients with 
unilateral malignancy as a delayed procedure) could 
potentially reduce complications, but this remains to be 
determined.
All patients in iBRA 
with 3-month 
follow-up 
(n=2081)
Submuscular or 
fascial (n=180)
Dermal sling 
(n=436)
Biological mesh 
(n=1121)
Synthetic mesh 
(n=236)
Pre-pectoral 
(n=42)
Other (n=63) Not 
known 
(n=11)
NMBRA 
outcomes 
at 
3 months
National Quality 
Criteria for 
Breast 
Reconstruction*
Reoperation 370; 18% (16–20) 30; 17% (12–23) 79; 18% (15–22) 193; 17% (15–20) 48; 20% (15–26) 9; 21% (10–37] 9; 14% (7–25) 2 5% <5%
Re-
admission
372; 18% (16–20) 31; 17% (12–24) 85; 19% (16–24) 185; 17% (14–19) 49; 21% (16–27) 10; 24% (12–40) 10; 16% (8–27) 2 16% <5%
Infection 522; 25%, (23–27) 39; 22% (16–28) 138; 32% (27–36) 251; 22% (20–25) 61; 26% (20–32) 11; 26% (14–42) 19; 30% 
(19–43)
3 25% <10%†
Implant loss 182; 9% (8–10) 17; 9% (6–15) 47; 11% (8–14) 90; 8% (7–10) 24; 10% (7–15) 3; 7% (2–20) 2; 3% (0–11) 1 9% <5%
Data are n; % (95% CI), n, or %. NMBRA=National Mastectomy and Breast Reconstruction Audit. *Oncoplastic Breast Reconstruction—Guidelines for Best Practice. †Acellular dermal matrix-assisted breast 
reconstruction procedures: joint guidelines from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons. There were 2108 patients with implant-based 
reconstruction, of whom 2081 (99%) were included in the outcome analysis: complete outcome data (event data for all four key outcomes) are available for 2078 patients , who have been included in the 
analysis 27 (1%) patients have no outcome data and were excluded from the analysis. Partial outcome data (event data for three of four outcomes) are available for three patients, who were included in the 
analysis and who were assumed to not have had the event for the fourth missing outcome.
Table 4: 3-month outcomes after implant-based breast reconstruction, by procedure type, compared with outcomes in NMBRA and UK National Quality Criteria for Breast Reconstruction
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The proportion of patients identified in this study who 
experienced implant loss, re-admission, and infection 
remain un changed since the 2008–09 NMBRA, whereas 
the proportion of patients requiring re-operation has 
more than tripled.24 The reasons for this increase are 
complex. The numbers of immediate implant-based 
breast recon struction have increased substantially since 
2008–09,5,22 but there is no evidence to suggest that the 
indications for implant-based surgery have changed, 
since the proportions of patients who smoked, had 
diabetes, had a high BMI, or were American Society of 
Anesthesiologists grades III/IV in our study are largely 
consistent with the NMBRA cohort.24 Increased numbers 
of re-operations could reflect more aggressive 
management of complications when mesh is used, 
but the use of mesh does not seem to translate into a 
reduced percentage of implant loss. Although the 
proportions of patients with implant loss and return to 
theatre in this study are much lower than those reported 
in a 2017 randomised trial,11,13 they are much higher than 
those reported in other large prospective observational 
studies14,15,28 and summarised in recent systematic 
reviews.8,9 This large, multicentre study is likely to reflect 
real-world outcomes of immediate implant-based breast 
reconstruction, and highlights the need for improvement 
in this area.
This national prospective study adds substantially to 
the evidence base in immediate implant-based breast 
reconstruction, but has several limitations. Firstly, it is a 
non-randomised study that will be subject to bias. 
Implant loss (n=1722) Infection (n=1722) Re-admission (n=1722) Reoperation (n=1722)
Age, years* 1·00 (0·98–1·02); p=0·87 1·01 (1·00–1·02); p=0·27 1·00 (0·99–1·01); p= 0·77 0·99 (0·98–1·01); p=0·35
Body-mass index (kg/m²)† 1·07 (1·03–1·11); p=0·0002 1·07 (1·04–1·10); p<0·0001 1·05 (1·03–1·08); p=0·0001 1·04 (1·01–1·07); p=0·0032
Operative time, min 1·00 (1·00–1·01); p=0·049 1·00 (1·00–1·00); p=0·073 1·00 (1·00–1·00); p=0·049 1·00 (1·00–1·01); p=0·013
Smoking
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1·92 (1·19–3·09); p=0·0074 1·53 (1·09–2·17); p=0·015 1·92 (1·33–2·77); p=0·0005 1·87 (1·30–2·70); p=0·0008
Previous radiotherapy to ipsilateral breast
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1·35 (0·70–2·60); p=0·37 1·72 (1·12–2·62); p=0·013 1·15 (0·69–1·91); p=0·59 1·24 (0·75–2·03); p=0·41
Neoadjuvant chemotherapy
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 0·64 (0·33–1·21); p=0·17 0·72 (0·48–1·08); p=0·11 0·82 (0·53–1·28); p=0·38 0·73 (0·47–1·15); p=0·18
Bilateral surgery
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1·72 (0·85–3·47); p=0·13 1·27 (0·81–1·97); p=0·30 1·24 (0·76–2·03); p=0·39 1·15 (0·70–1·90); p=0·58
Nipple-sparing mastectomy
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1·24 (0·80–1·92); p=0·33 1·09 (0·82–1·46); p=0·55 1·04 (0·75–1·44); p=0·81 1·20 (0·88–1·64); p=0·25
Risk-reducing surgery
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 0·87 (0·37–2·06); p=0·75 0·87 (0·48–1·56); p=0·64 1·13 (0·59–2·14); p=0·71 1·28 (0·68–2·41); p=0·45
Therapeutic mastectomy
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1·36 (0·69–2·69); p=0·38 0·80 (0·49–1·29); p=0·36 0·92 (0·55–1·54); p=0·74 1·11 (0·67–1·84); p=0·68
Fixed-volume implant
No 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 0·87 (0·60–1·26); p=0·46 0·92 (0·72–1·16); p=0·46 0·86 (0·66–1·13); p=0·27 0·90 (0·69–1·18); p=0·45
Type of IBBR
Biological mesh 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Dermal sling 0·85 (0·52–1·38); p=0·50 1·21 (0·89–1·64); p=0·22 0·91 (0·64–1·30); p=0·60 0·85 (0·59–1·22); p=0·38
Other 0·17 (0·02–1·25); p=0·082 1·34 (0·73–2·46); p=0·34 0·82 (0·39–1·74); p=0·60 0·80 (0·38–1·70); p=0·56
Pre-pectoral 0·91 (0·20–4·04); p=0·90 1·02 (0·39–2·66); p=0·96 1·92 (0·76–4·82); p=0·17 1·37 (0·52–3·60); p=0·52
Submuscular or fascial 1·06 (0·55–2·08); p=0·86 0·89 (0·56–1·41); p=0·63 1·03 (0·63–1·70); p=0·90 1·00 (0·61–1·63); p=0·98
Synthetic mesh 1·12 (0·66–1·90); p=0·68 1·13 (0·79–1·61); p=0·50 1·20 (0·81–1·78); p=0·37 1·09 (0·74–1·62); p=0·66
Data are odds ratio (95% CI); p value. IBBR=immediate implant-based breast reconstruction. *Increase in odds for each additional year. †Increase in odds for each additional 
body-mass index unit.
Table 5: Logistic regression of risk factors for key outcomes
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Notably, patients having dermal sling reconstruction had 
higher BMIs than did those in the other groups, but 
other, subtler, differences might exist between patients 
having different procedures that were not considered in 
this study. Despite defining outcomes, including implant 
loss, a priori, practice changed during the study period. 
Of particular note was the introduction of implant 
salvage procedures, whereby fixed-volume implants that 
were infected or exposed were debrided, washed out, 
and replaced either with a new implant or a tissue 
expander. This outcome was not considered to be an 
implant loss in our study, although the initial implant 
was removed. Infection was another controversial topic. 
We considered any redness requiring treatment with 
antibiotics in this category. We acknowledge that this 
might have overestimated the occurrence of implant 
infection, but reported frequencies were consistent 
those in the NMBRA.24 Clear, unambiguous definitions 
of outcomes will therefore be needed for future studies. 
Smoking, BMI, operative time, and previous 
radiotherapy were identified as risk factors for 
complications in this study, and this potential association 
might be informative when designing subsequent 
randomised clinical trials as a basis for balancing 
randomisation. Although this study was not powered to 
establish prognostic factors, and the results should be 
confirmed in an external validation study, consistency 
between these results and those in other studies29,30 
support these findings. Finally, complications were only 
assessed until 3 months. This approach would not 
capture complications, such as infection, which 
developed while patients were receiving chemotherapy 
or problems developing as a result of adjuvant 
radiotherapy, for which a longer period of follow-up 
would be required.
The findings of this large, non-randomised study 
strongly support the need for a randomised controlled 
trial in immediate implant-based breast reconstruction, 
and potential trial designs could include biological 
versus synthetic mesh or pre-pectoral versus sub-
pectoral implant placement. Before embarking on a full 
trial, a pilot randomised clinical trial is recommended, 
to establish whether recruitment is possible. 
Additionally, urgent work is also needed to improve 
outcomes for patients having immediate implant-based 
breast recon struction in the UK. The proportion of 
patients experiencing implant loss and infection and 
those requiring re-operation and re-admission do not 
appear to have improved (ie, decreased) since NMBRA, 
and do not meet published quality standards. Reasons 
for this finding are unclear, but non-compliance with 
best practice guidelines might be a contributory factor21 
and further investigation of variation by centre is 
planned. This study provides further evidence that 
increased BMI and smoking significantly increase the 
risk of compli cations after implant-based breast 
reconstruction. These factors are not immediately 
modifiable in the short-term, but neoadjuvant chemo-
therapy or endocrine therapy could be used as a strategy 
to provide patients with breast cancer with additional 
time to lose weight or stop smoking before surgery. 
Bilateral risk-reducing surgery, meanwhile, could be 
delayed until these risk factors had been addressed. An 
alternative solution would be to restrict the offer of 
immediate implant-based breast reconstruction to 
patients without risk factors. This approach might not 
be practical or ethical, and a more appropriate focus 
could be to develop effective strategies to help patients 
better understand the potential risks of surgery, to allow 
them to make fully informed decisions. Finally, reducing 
the observed variation might effectively improve 
outcomes, and this will be the focus of the UK Getting it 
Right First Time initiative. However, it is important that 
any standardisation of care reflects evidence-based best 
practice, and further exploratory analysis of the iBRA 
cohort will support this.
There remains the need for high-quality evidence from 
a randomised controlled trial to support the best practice 
of immediate implant-based breast reconstruction, and 
the equivalence of different techniques in this non-
randomised study supports a future randomised clinical 
trial. The outcomes of immediate implant-based breast 
reconstruction in the UK are poor and surgeons need to 
commit to robust evaluation if outcomes for patients are 
to be improved.
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author from months to 3 years after publication. To gain access, data 
requestors will need to sign a data access agreement.
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